Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference June 21, 2022 • 8:00 AM EDT
Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma June 15, 2022 • 9:00 AM EDT
Kintara Therapeutics to Present at the JMP Securities Life Sciences Conference June 10, 2022 • 9:00 AM EDT
Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement June 3, 2022 • 9:00 AM EDT
Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma May 27, 2022 • 9:30 AM EDT
Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update May 13, 2022 • 8:00 AM EDT
Kintara Announces Closing of $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules April 14, 2022 • 4:05 PM EDT
Kintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules April 12, 2022 • 8:30 AM EDT
Kintara Therapeutics Presents Data at the 2022 American Association for Cancer Research Annual Meeting April 11, 2022 • 2:30 PM EDT